Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Ruxolitinib ameliorates progressive anemia and improves survival during episodes of emergency granulopoiesis in Fanconi C–/– mice

Experimental Hematology(2022)10.1016/j.exphem.2022.03.001Source: DataRank Database

Ruxolitinib ameliorates progressive anemia and improves survival during episodes of emergency granulopoiesis in Fanconi C–/– mice is a research paper published in Experimental Hematology (2022). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.27)OA: hybridTopics (29)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Liping Hu ORCID,Olatundun Williams ORCID,Elizabeth A. Eklund ORCID,Shirin Hasan

Live enrichment

PubMed:35278531 PMC:PMC9064927 OpenAlex:https://openalex.org/W4221062407

National Institutes of Health

Grant: R01-DK121354

U.S. Department of Veterans Affairs

Grant: CX001864

BLRD VA

Grant: I01 BX004635

CSRD VA

Grant: I01 CX001864

NIDDK NIH HHS

Grant: R01 DK121354

Veterans Health Administration Biomedical Laboratory Research and Development

FWCI

0.27

Citation Percentile

0.5%

Citation Trend

2023

2024

hybridLicense: cc-by

journalhttps://doi.org/10.1016/j.exphem.2022.03.001

publisherhttps://doi.org/10.1016/j.exphem.2022.03.001

publisherhttps://api.elsevier.com/content/article/PII:S0301472X22001205?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0301472X22001205?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35278531

Fields of Study

Myeloproliferative Neoplasms: Diagnosis and TreatmentCytokine Signaling Pathways and InteractionsErythrocyte Function and Pathophysiology

MeSH Terms

AnimalsErythropoietinFanconi AnemiaHematopoiesisNitrilesPyrazolesPyrimidinesMice, KnockoutMiceFanconi Anemia Complementation Group ProteinsFanconi Anemia Complementation Group C Protein

Keywords

GranulopoiesisFanconi anemiaRuxolitinibMedicineAnemiaBone marrow failureInternal medicineHaematopoiesisBone marrowBiologyMyelofibrosisStem cellGeneticsDNA repairDNA

Sustainable Development Goals

SDG 0: Good health and well-being

Ruxolitinib ameliorates progressive anemia and improves survival during episodes of emergency granulopoiesis in Fanconi C–/– mice

FAIR Checklist

Authors (4)

Funding (6 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)